Adicet Bio Stock Price, News & Analysis (NASDAQ:ACET) $1.38 +0.01 (+0.73%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$1.27▼$1.4150-Day Range$1.11▼$1.6552-Week Range$1.10▼$19.84Volume302,863 shsAverage Volume570,167 shsMarket Capitalization$59.57 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Adicet Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside1,023.2% Upside$15.50 Price TargetShort InterestBearish9.98% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$15,125 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.90) to ($2.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector427th out of 954 stocksPharmaceutical Preparations Industry140th out of 362 stocks 3.3 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Adicet Bio has a forecasted upside of 1,023.2% from its current price of $1.38.Amount of Analyst CoverageAdicet Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.98% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Adicet Bio has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Adicet Bio this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.MarketBeat Follows2 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,125.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.29% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to grow in the coming year, from ($2.90) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adicet Bio Stock (NASDAQ:ACET)Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.Read More ACET Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACET Stock News HeadlinesDecember 7, 2023 | morningstar.comAdicet Bio Inc Ordinary SharesNovember 16, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN) and Adicet Bio (ACET)December 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | markets.businessinsider.comAdicet Bio: Buy Rating Driven by Strategic Overhaul and Promising Oncology DevelopmentsNovember 9, 2023 | markets.businessinsider.comWedbush Maintains Outperform Rating for Adicet Bio: Here's What You Need To KnowNovember 8, 2023 | seekingalpha.comAdicet Bio GAAP EPS of -$1.16November 8, 2023 | markets.businessinsider.comAdicet Bio, Inc Q3 Loss increases, misses estimatesNovember 7, 2023 | finance.yahoo.comAdicet Bio to Present at the 2023 Jefferies London Healthcare ConferenceDecember 8, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 2, 2023 | finance.yahoo.comAdicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual MeetingOctober 31, 2023 | finance.yahoo.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)October 4, 2023 | finance.yahoo.comAdicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics ConferenceSeptember 27, 2023 | finance.yahoo.comAdicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingSeptember 6, 2023 | msn.comTruist Securities Reiterates Adicet Bio (ACET) Buy RecommendationAugust 12, 2023 | finance.yahoo.comWill Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?August 11, 2023 | msn.comBTIG Maintains Adicet Bio (ACET) Buy RecommendationAugust 9, 2023 | finance.yahoo.comAdicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue EstimatesAugust 9, 2023 | markets.businessinsider.comAdicet Bio, Inc Q2 Loss increases, misses estimatesAugust 9, 2023 | finance.yahoo.comAdicet Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 3, 2023 | finance.yahoo.comAdicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 12, 2023 | benzinga.comAdicet Bio Director Awarded $236K Worth of Stock OptionsJuly 11, 2023 | finance.yahoo.comAdicet Announces Appointment of Katie Peng to the Board of DirectorsJuly 6, 2023 | msn.comAdicet Bio (ACET) Price Target Decreased by 12.90% to 24.48June 30, 2023 | benzinga.comMassive Insider Trade At Adicet BioJune 30, 2023 | benzinga.comDirector of Adicet Bio Purchased $1.83M In StockJune 27, 2023 | msn.comJMP downgrades Adicet to market perform, citing study delayJune 27, 2023 | msn.comAdicet Bio Stock Craters 54% after JMP DowngradeSee More Headlines Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors SectorMedical Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$27.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,023.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.82% Return on Assets-43.11% Debt Debt-to-Equity RatioN/A Current Ratio9.40 Quick Ratio9.40 Sales & Book Value Annual Sales$24.99 million Price / Sales2.38 Cash FlowN/A Price / Cash FlowN/A Book Value$6.82 per share Price / Book0.20Miscellaneous Outstanding Shares43,165,000Free Float30,431,000Market Cap$59.57 million OptionableOptionable Beta1.86 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Chen Schor BA (Age 51)CPA, M.B.A., CEO, President & Director Comp: $899.58kDr. Aya Jakobovits Ph.D. (Age 68)Founder & Independent Director Comp: $40kDr. Blake Aftab Ph.D. (Age 42)Senior VP & Chief Scientific Officer Comp: $675.04kDr. Francesco Galimi M.D. (Age 55)Ph.D., Chief Medical Officer & Senior VP Comp: $680.37kMr. Brian Nicholas Harvey (Age 62)Chief Financial Officer Comp: $596.79kDr. Donald Healey Ph.D. (Age 61)Chief Technology Officer Ms. Amy LockeHead of Human ResourcesDr. Nancy L. Boman M.D.Ph.D., Senior VP & Chief Regulatory OfficerMore ExecutivesKey CompetitorsAcurx PharmaceuticalsNASDAQ:ACXPImmunicNASDAQ:IMUXCleneNASDAQ:CLNNConnect BiopharmaNASDAQ:CNTBYS BiopharmaNASDAQ:YSView All CompetitorsInsiders & InstitutionsDecheng Capital Management III Cayman LLCSold 305,467 shares on 11/29/2023Ownership: 0.464%Jacobs Levy Equity Management Inc.Bought 9,437 shares on 11/17/2023Ownership: 0.773%GSA Capital Partners LLPBought 37,194 shares on 11/15/2023Ownership: 0.329%AQR Capital Management LLCBought 75,022 shares on 11/15/2023Ownership: 0.174%Northern Trust CorpSold 11,598 shares on 11/13/2023Ownership: 0.534%View All Insider TransactionsView All Institutional Transactions ACET Stock Analysis - Frequently Asked Questions Should I buy or sell Adicet Bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks. What is Adicet Bio's stock price target for 2024? 7 brokers have issued twelve-month price objectives for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,023.2% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts. How have ACET shares performed in 2023? Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 84.6% and is now trading at $1.38. View the best growth stocks for 2023 here. Are investors shorting Adicet Bio? Adicet Bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,030,000 shares, an increase of 6.7% from the October 31st total of 2,840,000 shares. Based on an average daily volume of 392,400 shares, the short-interest ratio is currently 7.7 days. Currently, 10.0% of the shares of the company are short sold. View Adicet Bio's Short Interest. When is Adicet Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our ACET earnings forecast. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Wednesday, November, 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. Is Adicet Bio a good dividend stock? Adicet Bio (NASDAQ:ACET) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.00%. Read our dividend analysis for ACET. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE). Who are Adicet Bio's major shareholders? Adicet Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (6.30%), Acadian Asset Management LLC (1.21%), Jacobs Levy Equity Management Inc. (0.77%), Northern Trust Corp (0.53%), Decheng Capital Management III Cayman LLC (0.46%) and GSA Capital Partners LLP (0.33%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACET) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.